IL239898B - Therapeutic compositions and methods involving mrna transfection - Google Patents

Therapeutic compositions and methods involving mrna transfection

Info

Publication number
IL239898B
IL239898B IL239898A IL23989815A IL239898B IL 239898 B IL239898 B IL 239898B IL 239898 A IL239898 A IL 239898A IL 23989815 A IL23989815 A IL 23989815A IL 239898 B IL239898 B IL 239898B
Authority
IL
Israel
Prior art keywords
processes involving
medicinal compositions
mrna transfection
involving mrna
transfection
Prior art date
Application number
IL239898A
Other languages
English (en)
Hebrew (he)
Other versions
IL239898A0 (en
Inventor
C Herzberg Mark
R Sorenson Brent
Farnie Ross Karen
Original Assignee
C Herzberg Mark
C Herzberg Mark
R Sorenson Brent
Farnie Ross Karen
Farnie Ross Karen
R Sorenson Brent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C Herzberg Mark, C Herzberg Mark, R Sorenson Brent, Farnie Ross Karen, Farnie Ross Karen, R Sorenson Brent filed Critical C Herzberg Mark
Publication of IL239898A0 publication Critical patent/IL239898A0/en
Publication of IL239898B publication Critical patent/IL239898B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL239898A 2013-01-11 2015-07-12 Therapeutic compositions and methods involving mrna transfection IL239898B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Publications (2)

Publication Number Publication Date
IL239898A0 IL239898A0 (en) 2015-08-31
IL239898B true IL239898B (en) 2018-10-31

Family

ID=51167392

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239898A IL239898B (en) 2013-01-11 2015-07-12 Therapeutic compositions and methods involving mrna transfection
IL262252A IL262252B (en) 2013-01-11 2018-10-10 Therapeutic compositions and methods involving mrna transfection

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL262252A IL262252B (en) 2013-01-11 2018-10-10 Therapeutic compositions and methods involving mrna transfection

Country Status (13)

Country Link
US (3) US20150344537A1 (cg-RX-API-DMAC10.html)
EP (2) EP2943226B1 (cg-RX-API-DMAC10.html)
JP (4) JP2016511230A (cg-RX-API-DMAC10.html)
KR (2) KR102056511B1 (cg-RX-API-DMAC10.html)
CN (1) CN105473163A (cg-RX-API-DMAC10.html)
AU (1) AU2014205298B2 (cg-RX-API-DMAC10.html)
CA (2) CA2901409C (cg-RX-API-DMAC10.html)
ES (1) ES2738315T3 (cg-RX-API-DMAC10.html)
IL (2) IL239898B (cg-RX-API-DMAC10.html)
NZ (1) NZ710495A (cg-RX-API-DMAC10.html)
PL (1) PL2943226T3 (cg-RX-API-DMAC10.html)
SG (2) SG10201603946PA (cg-RX-API-DMAC10.html)
WO (1) WO2014110366A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7754676B2 (en) * 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
WO2004089292A2 (en) * 2003-04-04 2004-10-21 The Regents Of The University Of California Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
CA2831613A1 (en) * 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection

Also Published As

Publication number Publication date
IL239898A0 (en) 2015-08-31
WO2014110366A1 (en) 2014-07-17
EP2943226B1 (en) 2019-03-13
PL2943226T3 (pl) 2019-09-30
SG11201505431XA (en) 2015-08-28
EP3501551C0 (en) 2023-06-07
US11912744B2 (en) 2024-02-27
EP2943226A4 (en) 2016-11-23
IL262252B (en) 2020-06-30
JP6473729B2 (ja) 2019-02-20
CN105473163A (zh) 2016-04-06
US20240166701A1 (en) 2024-05-23
US12448421B2 (en) 2025-10-21
US20200231640A1 (en) 2020-07-23
KR102056511B1 (ko) 2019-12-16
EP3501551B1 (en) 2023-06-07
JP2017052781A (ja) 2017-03-16
EP3501551A1 (en) 2019-06-26
KR20180026811A (ko) 2018-03-13
CA3152721C (en) 2025-11-18
ES2738315T3 (es) 2020-01-21
KR20160031999A (ko) 2016-03-23
JP2016511230A (ja) 2016-04-14
AU2014205298B2 (en) 2018-11-01
JP2019031521A (ja) 2019-02-28
EP2943226A1 (en) 2015-11-18
CA3152721A1 (en) 2014-07-17
KR102119985B1 (ko) 2020-06-05
CA2901409C (en) 2022-06-07
AU2014205298A1 (en) 2015-08-13
JP6956059B2 (ja) 2021-10-27
NZ710495A (en) 2019-10-25
US20150344537A1 (en) 2015-12-03
CA2901409A1 (en) 2014-07-17
IL262252A (en) 2018-11-29
JP2021019644A (ja) 2021-02-18
SG10201603946PA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
IL269045B (en) Aptamers and uses thereof
IL286759A (en) Therapeutic methods and preparations
EP2953474A4 (en) COMPOSITIONS AND METHODS
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
PL2969227T3 (pl) Formulacja octanu abirateronu
HRP20181994T1 (hr) Neuroaktivni steroidi i postupci za njihovu upotrebu
ME03465B (me) Farmaceutska kompozicija s-ketamin hidrohlorida
DK3038674T3 (da) Medikamentafgivelsesindretning
DK3049117T3 (da) Ultralydsmedieret afgivelse af lægemidler
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
DK3027750T3 (da) Biokatalytisk sammensætning
SG11201508167PA (en) Therapeutic compositions and uses thereof
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
IL282430A (en) Anti-cancer agents and preparation thereof
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
DK3068505T3 (da) Spillesystem og -fremgangsmåde
PL3042669T3 (pl) Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
PL3228313T3 (pl) Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
EP2996685A4 (en) FLUID PROCESSING COMPOSITIONS AND METHODS
FR3007291B1 (fr) Composition cicatrisante et utlisation
DK2983747T3 (da) Lægemiddelindgivelsesindretning

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed